Seventh Consecutive Quarter of Double-Digit Revenue Growth
Quanterix reported its seventh consecutive quarter of double-digit revenue growth, with a total revenue of $35.2 million, marking an 11% increase year-over-year.
Strong Performance in Accelerator Lab
The Accelerator lab revenue grew by 22% in the quarter, driven by capacity expansion and strong demand for clinical trials and custom assay development.
Non-GAAP Gross Margin Improvement
Non-GAAP gross margin improved by 300 basis points to 57.7% in the fourth quarter, driven by higher pricing and improved operating efficiency.
Significant Expansion in Recurring Revenues
Recurring revenues increased from 65% to 80% over two years, contributing to a revenue CAGR of 14%.
Acquisition of Akoya Biosciences
The planned acquisition of Akoya Biosciences is expected to expand Quanterix's research addressable market from $1 billion to $5 billion, and diagnostics TAM from $10 billion to $15 billion.